feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouUnited StatesUnited States
You
bookmarksYour BookmarkshashtagYour Topics
Trending
Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2026 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / Cold Severity Tied to Immune Response

Cold Severity Tied to Immune Response

2 Feb

•

Summary

  • Immune programs in nasal tissue determine rhinovirus infection severity.
  • Lab-grown 'noses-in-a-dish' mimic human nasal passages for study.
  • Findings may lead to new antiviral treatments for common colds.
Cold Severity Tied to Immune Response

New laboratory experiments have revealed that the varied severity of rhinovirus infections is determined by the activation of distinct immune programs within nasal tissue. Researchers utilized "noses-in-a-dish" models, essentially miniature human nasal passages grown in a lab, to study cellular responses to infection.

These findings, published recently in Cell Press Blue, highlight that how severely a rhinovirus affects an individual can depend on the specific immune pathways triggered. This research is a significant step toward developing targeted antiviral therapies for the common cold.

Scientists employed single-cell RNA sequencing on nasal epithelial cells to understand their interaction with rhinoviruses. When interferon signaling was suppressed, the cells showed a more pronounced and prolonged immune response, resembling severe infection outcomes seen in vulnerable patients.

This detailed cellular-level understanding could inform the development of treatments. For instance, an experimental antiviral drug, rupintrivir, showed promise in subduing overactive immune responses in lab models, suggesting potential use in vulnerable groups. However, targeting viral proteins directly might offer more precision than broadly inhibiting immune responses.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
Distinct immune programs activated within nasal tissue determine whether a rhinovirus infection causes mild illness or severe complications.
'Noses-in-a-dish' are laboratory models of human nasal passages used to study how cells react to rhinovirus infections.
Yes, the findings provide insights that may lead to the development of effective antiviral treatments for the common cold, especially for vulnerable individuals.

Read more news on

Healthside-arrow
trending

Ohio snow emergency declared

trending

TikTok down in United States

trending

Andreeva matches Venus Williams' feat

trending

Warrington Hospital baby death

trending

Alexander Zverev advances in Australia

trending

Oilers host Capitals

trending

London celebrates Chinese New Year

trending

Liza Minnelli defends AI use

You may also like

Common Virus Triggers Severe Brain Infections

24 Jan • 32 reads

article image

New Study Reveals Cold's Nasal Battleground

21 Jan • 46 reads

article image

New Year, New Viral Threats: What to Watch in 2026

18 Jan • 128 reads

article image

Winter Woes: City Hospitals See Surge in Cold, Cough Cases

9 Jan • 130 reads

article image

Winter Germs Alert: Flu, COVID, RSV Surge Expected

16 Dec, 2025 • 273 reads